Core Insights - Adaptive Biotechnologies Corporation is participating in the 44th Annual J.P. Morgan Healthcare Conference in San Francisco, CA on January 12, 2026 [1][2] Company Overview - Adaptive Biotechnologies is a commercial-stage biotechnology company focused on leveraging the adaptive immune system for disease diagnosis and treatment [3] - The company aims to decode the adaptive immune system's genetics to enhance its diagnostic and therapeutic capabilities [3] - Its proprietary immune medicine platform is designed to translate the genetics of the adaptive immune system with scale, precision, and speed [3] - The company operates in two business segments: Minimal Residual Disease (MRD) and Immune Medicine, developing clinical diagnostics and partnering with biopharmaceutical companies [3] - The goal is to create immune-driven clinical products tailored to individual patients for diseases such as cancer and autoimmune disorders [3]

Core Insights - Adaptive Biotechnologies has entered into two non-exclusive agreements with Pfizer to utilize its T-cell receptor (TCR) discovery capabilities and immune receptor antigen mapping data for research in rheumatoid arthritis (RA) [1][3][5] Group 1: Agreements Overview - The first agreement focuses on identifying disease-causing TCRs in RA, where Adaptive will analyze Pfizer's clinical samples to find common TCRs enriched in RA patients [3] - The second agreement involves licensing Adaptive's TCR-antigen datasets, which are claimed to be the largest and highest quality available, for use in developing AI and machine learning models at Pfizer [4][6] Group 2: Financial Aspects - Adaptive will receive an upfront payment from Pfizer and may be eligible for additional payments that could total up to approximately $890 million, contingent on data delivery, development, and commercialization milestones [5] - Specific financial terms of the TCR-antigen data licensing agreement have not been disclosed, but it is a multi-year, non-exclusive agreement [6] Group 3: Company Background - Adaptive Biotechnologies is a commercial-stage biotechnology company focused on leveraging the adaptive immune system for disease diagnosis and treatment, with a goal to develop immune-driven clinical products tailored to individual patients [7]

Core Insights - Adaptive Biotechnologies Corporation will report its financial results for Q3 2025 on November 5, 2025, after market close [1] - A conference call will follow the financial results announcement, starting at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time [1] Company Overview - Adaptive Biotechnologies is a commercial-stage biotechnology company focused on utilizing the adaptive immune system's biology to develop clinical products for disease diagnosis and treatment [3] - The company aims to decode the adaptive immune system to enhance its diagnostic and therapeutic capabilities, which have been underutilized due to previous decoding challenges [3] - The proprietary immune medicine platform of the company allows for the translation of the adaptive immune system's genetics with scale, precision, and speed [3] - The company operates in two business segments: Minimal Residual Disease (MRD) and Immune Medicine, providing products and clinical pipelines for diseases like cancer and autoimmune disorders [3] - The goal is to create and commercialize immune-driven clinical products tailored to individual patients [3]

Core Insights - Adaptive Biotechnologies Corporation will report its financial results for Q2 2025 on August 5, 2025, after market close [1] - A conference call will follow the financial results announcement, starting at 1:30 p.m. Pacific Time [1] Company Overview - Adaptive Biotechnologies is a commercial-stage biotechnology company focused on utilizing the adaptive immune system for disease diagnosis and treatment [3] - The company aims to decode the adaptive immune system's genetics to enhance medical capabilities in diagnosing and treating diseases [3] - Its proprietary immune medicine platform is designed to provide scalable, precise, and rapid insights into the adaptive immune system [3] - The company operates in two business segments: Minimal Residual Disease (MRD) and Immune Medicine, targeting diseases such as cancer and autoimmune disorders [3] - The goal is to develop and commercialize immune-driven clinical products tailored to individual patients [3]